
Anne Sophie Kubasch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2752708/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncology, The, 2018, 19, 1668-1679.	10.7	250
2	Randomized controlled trials – a matter of design. Neuropsychiatric Disease and Treatment, 2016, 12, 1341.	2.2	159
3	Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1β expression and release. Clinical Immunology, 2015, 161, 300-307.	3.2	88
4	Serum biomarkers for the diagnosis and monitoring of chronic recurrent multifocal osteomyelitis (CRMO). Rheumatology International, 2016, 36, 769-779.	3.0	61
5	CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease. Blood, 2021, 138, 1727-1732.	1.4	58
6	Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia, 2021, 35, 2182-2198.	7.2	46
7	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. Journal of Clinical Medicine, 2019, 8, 1534.	2.4	41
8	Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia, 2020, 34, 1182-1186.	7.2	39
9	Development of luspatercept to treat ineffective erythropoiesis. Blood Advances, 2021, 5, 1565-1575.	5.2	39
10	Laser Doppler Assessment of Vasomotor Axon Reflex Responsiveness to Evaluate Neurovascular Function. Frontiers in Neurology, 2017, 8, 370.	2.4	26
11	Iron overload and its impact on outcome of patients with hematological diseases. Molecular Aspects of Medicine, 2020, 75, 100868.	6.4	25
12	AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates NaÃ ⁻ ve and Treatment-Resistant Leukemia. Cancer Discovery, 2021, 11, 2924-2943.	9.4	20
13	Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes. International Journal of Molecular Sciences, 2019, 20, 3853.	4.1	18
14	Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML. Cancers, 2018, 10, 158.	3.7	15
15	Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial. Blood, 2018, 132, 4045-4045.	1.4	15
16	Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease (CAPTURE PD): Protocol for a Multicenter Study. Frontiers in Neurology, 2017, 8, 212.	2.4	14
17	Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned. Blood Reviews, 2021, 50, 100851.	5.7	14
18	Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia. Blood Advances, 2018, 2, 1187-1190.	5.2	8

ANNE SOPHIE KUBASCH

#	Article	IF	CITATIONS
19	Patient stratification in myelodysplastic syndromes: how a puzzle may become a map. Hematology American Society of Hematology Education Program, 2020, 2020, 418-425.	2.5	6
20	Allogeneic Hematopoietic Stem Cell Transplantation in a Rare Case of Tonsillar Mast Cell Sarcoma. Frontiers in Oncology, 2020, 10, 219.	2.8	6
21	Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape. Neoplasia, 2021, 23, 1101-1109.	5.3	6
22	Disease management of patients with immune thrombocytopenia—results of a representative retrospective survey in Germany. Annals of Hematology, 2020, 99, 2085-2093.	1.8	4
23	Efficacy and Safety of Bemcentinib in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Failing Hypomethylating Agents. Blood, 2020, 136, 37-38.	1.4	4
24	The wolf of hypomethylating agent failure: what comes next?. Haematologica, 2019, 104, 1505-1508.	3.5	3
25	Predicting Early Relapse for Patients with Multiple Myeloma through Machine Learning. Blood, 2021, 138, 2953-2953.	1.4	3
26	Impact of <scp><i>PPM1D</i></scp> mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. American Journal of Hematology, 2021, 96, E207-E210.	4.1	2
27	Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse: Results of the Second Cohort of the RELAZA2 Trial. Blood, 2019, 134, 644-644.	1.4	2
28	Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q): A Case Series. Frontiers in Oncology, 2022, 12, 866470.	2.8	2
29	The Role of PPM1D Mutations in Lenalidomide Resistance and Progression in Patients with MDS and Deletion of Chromosome 5q. Blood, 2018, 132, 4360-4360.	1.4	1
30	Characterization of Somatic Mosaicism and Mutational Profiling of Clonal Hematopoiesis Compared to MDS and sAML Depicts Diversities of Clonal Evolution. Blood, 2021, 138, 3278-3278.	1.4	1
31	Facing the challenge: Novel treatment options for patients with myelodysplastic syndromes. HemaSphere, 2018, 2, 135-137.	2.7	1
32	Young Enough to Undergo Allogeneic Transplantation for Myelodysplastic Syndromes?. JAMA Oncology, 2020, 6, 493.	7.1	0
33	Aicardi-Goutières Syndrome (AGS1–AGS7). , 2019, , 1-5.		0
34	Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network. Blood, 2019, 134, 2998-2998.	1.4	0
35	Myelodysplastische Syndrome (MDS). , 2020, , 403-417.		0
36	Aicardi-Goutières Syndrome (AGS1–AGS7). , 2020, , 9-13.		0

#	Article	IF	CITATIONS
37	Hematopoietic Cell Transplantation for MDS Patients. , 2020, , 165-173.		0
38	GynÄ k ologische Tumoren. , 2020, , 863-898.		0
39	A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia. Blood, 2020, 136, 44-45.	1.4	0